{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:58:49Z","timestamp":1792619929956,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.pbb.2019.172794","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T20:37:20Z","timestamp":1571776640000},"page":"172794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice"],"prefix":"10.1016","volume":"187","author":[{"given":"Hiroshi","family":"Yukitake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Rikimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohisa","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhide","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.pbb.2019.172794_bb0005","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11940-016-0429-y","article-title":"Management of narcolepsy","volume":"18","author":"Barateau","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"issue":"4","key":"10.1016\/j.pbb.2019.172794_bb0010","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.pbb.2019.172794_bb0015","doi-asserted-by":"crossref","first-page":"16726","DOI":"10.1074\/jbc.M111.223537","article-title":"Temporal profiling of orexin receptor-arrestin-ubiquitin complexes reveals differences between receptor subtypes","volume":"286","author":"Dalrymple","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.pbb.2019.172794_bb0020","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12031-015-0536-3","article-title":"Interaction between brain histamine and serotonin, norepinephrine, and dopamine system: in vivo microdialysis and electrophysiology study","volume":"56","author":"Flink","year":"2015","journal-title":"J. Mol. Neurosci."},{"issue":"8","key":"10.1016\/j.pbb.2019.172794_bb0025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/sleep\/26.8.953","article-title":"Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog","volume":"26","author":"Fujiki","year":"2003","journal-title":"Sleep"},{"issue":"21","key":"10.1016\/j.pbb.2019.172794_bb0030","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1016\/j.bmcl.2011.08.093","article-title":"Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists","volume":"21","author":"Fujimoto","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.pbb.2019.172794_bb0035","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3949\/ccjm.85a.17086","article-title":"Narcolepsy: diagnosis and management","volume":"85","author":"Golden","year":"2018","journal-title":"Cleve. Clin. J. Med."},{"issue":"16","key":"10.1016\/j.pbb.2019.172794_bb0040","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.yexcr.2012.04.015","article-title":"OX2R activation induces PKC-mediated ERK and CREB phosphorylation","volume":"318","author":"Guo","year":"2012","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.pbb.2019.172794_bb0045","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.pbb.2019.172794_bb0050","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5664\/jcsm.2912","article-title":"Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study","volume":"9","author":"Inoue","year":"2013","journal-title":"J. Clin. Sleep Med."},{"issue":"22","key":"10.1016\/j.pbb.2019.172794_bb0055","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1073\/pnas.1700499114","article-title":"Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models","volume":"114","author":"Irukayama-Tomobe","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pbb.2019.172794_bb1000","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/7854_2016_47","article-title":"Orexin OX2 receptor antagonists as sleep aids","volume":"33","author":"Jacobson","year":"2017","journal-title":"Curr Top Behav Neurosci"},{"issue":"1","key":"10.1016\/j.pbb.2019.172794_bb0060","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"3","key":"10.1016\/j.pbb.2019.172794_bb0065","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pbb.2019.172794_bb0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/cne.1190","article-title":"Differential expression of orexin receptors 1 and 2 in the rat brain","volume":"435","author":"Marcus","year":"2001","journal-title":"J. Comp. Neurol."},{"issue":"13","key":"10.1016\/j.pbb.2019.172794_bb0075","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1073\/pnas.0400590101","article-title":"Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice","volume":"101","author":"Mieda","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"17","key":"10.1016\/j.pbb.2019.172794_bb0080","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","article-title":"Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep","volume":"31","author":"Mieda","year":"2011","journal-title":"J. Neurosci."},{"issue":"8","key":"10.1016\/j.pbb.2019.172794_bb0085","first-page":"1119","article-title":"Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy","volume":"31","author":"Mishima","year":"2008","journal-title":"Sleep"},{"issue":"20","key":"10.1016\/j.pbb.2019.172794_bb0090","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","article-title":"Design and synthesis of non-peptide, selective Orexin receptor 2 agonists","volume":"58","author":"Nagahara","year":"2015","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.pbb.2019.172794_bb0095","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0006-8993(00)02555-5","article-title":"Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system","volume":"873","author":"Nakamura","year":"2000","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.pbb.2019.172794_bb0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.smrv.2005.03.004","article-title":"Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin\/orexin system","volume":"9","author":"Nishino","year":"2005","journal-title":"Sleep Med. Rev."},{"issue":"9197","key":"10.1016\/j.pbb.2019.172794_bb0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pbb.2019.172794_bb0110","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2012"},{"issue":"9","key":"10.1016\/j.pbb.2019.172794_bb0115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.pbb.2019.172794_bb0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.phrs.2016.01.031","article-title":"Recent updates on GPCR biased agonism","volume":"112","author":"Pupo","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.pbb.2019.172794_bb0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.pbb.2019.172794_bb0130","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pbb.2019.172794_bb0135","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders-third edition: highlights and modifications","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.pbb.2019.172794_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/sleep\/zsy183","article-title":"Histamine: neural circuits and new medications","volume":"42","author":"Scammell","year":"2019","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.pbb.2019.172794_bb0145","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.pbb.2019.172794_bb0150","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11940-015-0347-4","article-title":"Update on therapy for narcolepsy","volume":"17","author":"Thorpy","year":"2015","journal-title":"Curr. Treat. Options Neurol."},{"issue":"2","key":"10.1016\/j.pbb.2019.172794_bb0155","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/pr.109.001321","article-title":"Orexin\/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system","volume":"61","author":"Tsujino","year":"2009","journal-title":"Pharmacol. Rev."},{"issue":"7","key":"10.1016\/j.pbb.2019.172794_bb0160","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.tips.2014.04.007","article-title":"Biased ligands at G-protein-coupled receptors: promise and progress","volume":"35","author":"Violin","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.pbb.2019.172794_bb0165","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","article-title":"Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes","volume":"38","author":"Willie","year":"2003","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.pbb.2019.172794_bb0170","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.cellsig.2013.07.025","article-title":"Orexin receptors: multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders","volume":"25","author":"Xu","year":"2013","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.pbb.2019.172794_bb0175","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1254\/jphs.92.259","article-title":"Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins","volume":"92","author":"Zhu","year":"2003","journal-title":"J. Pharmacol. Sci."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305719304587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305719304587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:37:11Z","timestamp":1758775031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305719304587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":36,"alternative-id":["S0091305719304587"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2019.172794","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2019.172794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"172794"}}